IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio (Nasdaq: INAB) announced an upcoming plenary oral presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2024. The presentation will provide extended follow-up data from the Phase 1 trial of INB-200, their gamma-delta T cell therapy for newly diagnosed glioblastoma.
Previous data presented at ASCO in June 2024 showed that 92% of evaluable patients exceeded the median progression-free survival of 7 months typically observed with standard-of-care therapy. The presentation will be delivered by Dr. Mina Lobbous from Cleveland Clinic Lerner College of Medicine.
IN8bio (Nasdaq: INAB) ha annunciato una prossima presentazione orale plenaria alla 29ª Conferenza Annuale della Society for Neuro-Oncology (SNO) prevista per novembre 2024. La presentazione fornirà dati di follow-up estesi dal trial di Fase 1 di INB-200, la loro terapia con cellule T gamma-delta per i glioblastomi newly diagnosticati.
I dati precedenti presentati all'ASCO nel giugno 2024 hanno mostrato che il 92% dei pazienti evaluabili ha superato la mediana della sopravvivenza libera da progressione di 7 mesi tipicamente osservata con la terapia standard. La presentazione sarà tenuta dalla Dott.ssa Mina Lobbous del Cleveland Clinic Lerner College of Medicine.
IN8bio (Nasdaq: INAB) anunció una próxima presentación plenaria oral en la 29ª Reunión Anual de la Society for Neuro-Oncology (SNO) en noviembre de 2024. La presentación proporcionará datos de seguimiento ampliados del ensayo de Fase 1 de INB-200, su terapia con células T gamma-delta para glioblastoma recién diagnosticado.
Datos anteriores presentados en ASCO en junio de 2024 mostraron que el 92% de los pacientes evaluables superaron la mediana de supervivencia libre de progresión de 7 meses que se observa típicamente con la terapia estándar. La presentación será realizada por la Dra. Mina Lobbous del Cleveland Clinic Lerner College of Medicine.
IN8bio (Nasdaq: INAB)는 2024년 11월에 열리는 제29회 신경종양학회(SNO) 연례회의에서 발표할 예정이다. 이번 발표에서는 새로 진단된 교모세포종에 대한 그들의 감마 델타 T 세포 치료제인 INB-200의 1상 시험에서의 연장된 후속 데이터가 제공될 예정이다.
2024년 6월 ASCO에서 발표된 이전 데이터에 따르면, 평가 가능한 환자 중 92%가 표준 치료에서 일반적으로 관찰되는 7개월의 진행 없는 생존 미만을 초과했다. 발표는 클리블랜드 클리닉 레너 의대의 미나 로부스 박사가 진행할 예정이다.
IN8bio (Nasdaq: INAB) a annoncé une prochaine présentation orale plénière lors de la 29e Réunion Annuelle de la Society for Neuro-Oncology (SNO) prévue pour novembre 2024. La présentation fournira des données de suivi prolongées de l'essai de Phase 1 de INB-200, leur thérapie par cellules T gamma-delta pour les glioblastomes récemment diagnostiqués.
Les données précédemment présentées lors de l'ASCO en juin 2024 ont montré que 92 % des patients évaluables ont dépassé la médiane de survie sans progression de 7 mois généralement observée avec le traitement standard. La présentation sera réalisée par la Dr Mina Lobbous du Cleveland Clinic Lerner College of Medicine.
IN8bio (Nasdaq: INAB) kündigte eine bevorstehende plenare mündliche Präsentation auf dem 29. Jahrestreffen der Society for Neuro-Oncology (SNO) im November 2024 an. Die Präsentation wird erweiterte Nachfalldaten aus der Phase-1-Studie von INB-200, ihrer Gamma-Delta-T-Zelltherapie für neu diagnostiziertes Glioblastom, bereitstellen.
Zuvor präsentierte Daten auf der ASCO im Juni 2024 zeigten, dass 92% der bewertbaren Patienten die mediane progressionsfreie Überlebenszeit von 7 Monaten, die typischerweise mit der Standardtherapie beobachtet wird, überschritten. Die Präsentation wird von Dr. Mina Lobbous vom Cleveland Clinic Lerner College of Medicine gehalten.
- 92% of evaluable patients exceeded median progression-free survival compared to standard therapy
- Selection for plenary presentation at major industry conference indicates significant clinical findings
- None.
Insights
This upcoming presentation at SNO warrants attention but is not immediately market-moving. The key highlight is that 92% of evaluable patients exceeded the typical 7-month median progression-free survival seen with standard care, which was previously reported at ASCO in June. While promising for IN8bio's gamma-delta T cell therapy in glioblastoma treatment, this is essentially a preview of upcoming data presentation rather than new clinical results.
For a micro-cap company (
- Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM)
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), being hosted November 21 – 24, 2024 in Houston, TX. IN8bio will provide longer-term follow-up and additional data demonstrating the activity of its DRI gamma-delta T cell approach in solid tumors from the Phase 1 trial of INB-200. In June 2024, preliminary clinical data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating that
Details for the SNO oral presentation are as follows:
Title: INB-200: Fully Enrolled Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance Temozolomide (TMZ)
Presenter: Mina Lobbous, MD, MSPH, Assistant Professor, Cleveland Clinic Lerner College of Medicine
Abstract #: CTIM-09
Session Name: Abstract Session – Clinical Trials
Date and Time: Saturday, November 23, 2024, 11:25 AM - 11:35 AM CST
The abstract will be available online and can be accessed via the conference website at SNO 29th Annual Meeting & Education Day.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on evaluating haplo-matched allogenic gamma-delta T cells given to patients with AML following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.
Investor & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@in8bio.com
Patrick McCall
IN8bio, Inc.
646.933.5603
pfmccall@IN8bio.com
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
What are the latest clinical trial results for IN8bio's INB-200 (INAB stock)?
When will IN8bio (INAB) present their INB-200 glioblastoma trial data at SNO 2024?
What type of therapy is IN8bio's INB-200 (INAB)?
